| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 09/09/2003 | US6617457 Hydrogenolysis of the benzyl ester of quinapril in an alcoholic solvent, with hydrochloric acid and hydrogenation; removal of the solvent; addition of toluene to precipitate the product as a solvate |
| 09/09/2003 | US6617450 P-glycoproteins and uses thereof |
| 09/09/2003 | US6617440 Isolated polynucleotide that promotes transcription; gene expression inhibition; used for engineering animals with increased lean meat and promoting muscle growth; treating muscular disorders |
| 09/09/2003 | US6617430 Ataxin-2 binding proteins |
| 09/09/2003 | US6617428 Immunoglobulin M(IgM); given amino acid sequence; immunomodulators; use in blocking or inhibiting humoral immune responses in transplant patients |
| 09/09/2003 | US6617426 Peptide analogs of given formula; useful in treating neurodegenerative, autoimmune, cognitive disorders, stroke and traumatic injury |
| 09/09/2003 | US6617359 4-fluoro-N-indan-2-yl benzamide and its use as a pharmaceutical |
| 09/09/2003 | US6617352 Compounds and methods for the inhibition of the expression of VCAM-1 |
| 09/09/2003 | US6617348 Treating or preventing osteoporosis |
| 09/09/2003 | US6617347 Selective β3 adrenergic agonists |
| 09/09/2003 | US6617346 Inhibit the interaction of MDM2 protein with a p53-like peptide and have antiproliferative activity |
| 09/09/2003 | US6617333 Antineoplastic combinations comprising |
| 09/09/2003 | US6617327 For therapy of depression and other diseases such as obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders |
| 09/09/2003 | US6617326 Imidazo-triazine derivatives as ligands for GABA receptors |
| 09/09/2003 | US6617324 Substituted pyrazoles as p38 kinase inhibitors |
| 09/09/2003 | US6617322 Administering a piperazine or piperidine coupled through a linker to a benzhydril |
| 09/09/2003 | US6617317 Boronic ester and acid compositions |
| 09/09/2003 | US6617311 Effecting an increase in the amount of TH within the CNS through increasing the effective amount of an analog of Gly-Pro-Glu tripeptide (GPE) within the CNS of said patient; analog may be GP or PE. t |
| 09/09/2003 | US6617306 Therapeutic agent is conjugated to the carrier via a biodegradable disulfide bond. |
| 09/09/2003 | US6617157 Using inactivating agent of given formula to inactivate any virus contained in donor blood, blood products, or other biological compositions; can also use in vaccines |
| 09/09/2003 | US6617110 Cultured cell comprising a nucleic acid sequence, encoding the protein, that hybridizes to a polynucleotide of given sequence; use to determine if drug is cytotoxic; can use as anticarcinogenic agent |
| 09/09/2003 | US6617102 Screening for a bioactive agent capable of interfering with the binding of a protein; use in diagnosis and treatment of cancer |
| 09/09/2003 | CA2263566C Substituted 6,5-hetero-bicyclic derivatives |
| 09/09/2003 | CA2248953C Novel benzofuranone derivatives and process for producing the same |
| 09/09/2003 | CA2130174C 4-oxo-2 thioxoimidazolidine derivatives as inhibitors of blood platelet aggregation |
| 09/07/2003 | CA2412065A1 Use of agent for suppressing infection and proliferation of human immunodeficiency syndrome virus |
| 09/04/2003 | WO2003073099A1 Method for diagnosing and monitoring hemostatic dysfunction, severe infection and systematic inflammatory response syndrome |
| 09/04/2003 | WO2003073097A2 Methods for isolating ligands e.g. t cell epitopes |
| 09/04/2003 | WO2003072821A2 Method and nucleic acids for the analysis of a colon cell proliferactive disorder |
| 09/04/2003 | WO2003072820A2 Method and nucleic acids for the analysis of colon cell proliferative disorders |
| 09/04/2003 | WO2003072812A2 Method and nucleic acids for the analysis of colorectal cell proliferative disorders |
| 09/04/2003 | WO2003072802A2 Carboxyfullerenes and methods of use thereof |
| 09/04/2003 | WO2003072801A2 Compositions and method for regulation of calcium-dependent signalling in brain |
| 09/04/2003 | WO2003072789A2 Microorganisms as carriers of nucleotide sequences coding for cell antigens used for the treatment of tumors |
| 09/04/2003 | WO2003072780A1 Novel proteins, dnas thereof and use of the same |
| 09/04/2003 | WO2003072779A1 Method of using pituitary-specific genes |
| 09/04/2003 | WO2003072740A2 Novel type-1 cytokine receptor glm-r |
| 09/04/2003 | WO2003072704A2 RNA INTERFERENCE MEDIATED INHIBITION OF PLATELET DERIVED GROWTH FACTOR (PDGF) AND PLATELET DERIVED GROWTH FACTOR RECEPTOR (PDGFR) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 09/04/2003 | WO2003072604A1 Transmembrane nfat inhibitory peptide |
| 09/04/2003 | WO2003072591A1 Trpm-2 antisense therapy using an oligonucleotide having 2'-o-(2-methoxyl)ethyl modifications |
| 09/04/2003 | WO2003072579A1 HETEROARYL SUBSTITUTED 2-PYRIDINYL AND 2-PYRIMIDINYL -6,7,8,9- TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE DERIVATIVES |
| 09/04/2003 | WO2003072578A1 Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity |
| 09/04/2003 | WO2003072577A1 Thiazole derivatives as npy receptor antagonists |
| 09/04/2003 | WO2003072576A2 Oxazolidinone derivatives, processes for their preparation, and pharmaceutical compositions containing them |
| 09/04/2003 | WO2003072572A1 Beta3-adrenergic receptor agonists |
| 09/04/2003 | WO2003072570A1 Antidiabetic agents |
| 09/04/2003 | WO2003072569A1 1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases |
| 09/04/2003 | WO2003072565A1 Process for the production of citalopram |
| 09/04/2003 | WO2003072559A1 Method for producing 3-amidinophenylalanine derivatives |
| 09/04/2003 | WO2003072558A2 Arylsulfone derivatives |
| 09/04/2003 | WO2003072557A1 5-phenylthiazole derivatives and use as pi3 kinase inhibitors |
| 09/04/2003 | WO2003072556A1 Glutaminyl based dpiv inhibitors |
| 09/04/2003 | WO2003072554A1 Azole compounds |
| 09/04/2003 | WO2003072550A1 Novel fused ring indazole compounds |
| 09/04/2003 | WO2003072549A1 Farnesyl protein transferase inhibitors as antitumor agents |
| 09/04/2003 | WO2003072545A1 Cyclic amine compound and ccr3 inhibitory drug containing the same as active ingredient |
| 09/04/2003 | WO2003072543A2 Methods of preventing or treating brain ischemia or brain injury |
| 09/04/2003 | WO2003072539A1 Phenethanolamine derivatives for treatment of respiratory diseases |
| 09/04/2003 | WO2003072195A2 Method for administering glp-1 molecules |
| 09/04/2003 | WO2003072159A1 N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine coated stents |
| 09/04/2003 | WO2003072139A1 Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative |
| 09/04/2003 | WO2003072138A1 Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents |
| 09/04/2003 | WO2003072137A1 Combinations of (a) an atp- competitive inhibitor of c-abl kinase activity with (b) two or more other antineoplastic agents |
| 09/04/2003 | WO2003072130A1 Oxygen carrier system, artificial oxygen carrier and reducing agent |
| 09/04/2003 | WO2003072120A1 The use of the total coumarins of cnidium monnieri in preparation of the medicament for treating psoriasis |
| 09/04/2003 | WO2003072119A1 External compositions for the skin |
| 09/04/2003 | WO2003072114A1 Vascular therapeutics |
| 09/04/2003 | WO2003072110A1 Use of biogenic estriol diester prodrugs for the treatment of autoimmune diseases |
| 09/04/2003 | WO2003072109A1 Use of biogenic estriol sulfamate prodrugs for the treatment of autoimmune diseases |
| 09/04/2003 | WO2003072108A1 Novel crystalline forms of the anti-cancer compound zd1839 |
| 09/04/2003 | WO2003072107A1 Substituted pyrimidinones and pyrimidinthiones |
| 09/04/2003 | WO2003072102A1 Peroxisome proliferator activated receptor modulators |
| 09/04/2003 | WO2003072100A1 Peroxisome proliferator activated receptor modulators |
| 09/04/2003 | WO2003072098A1 Use of substituted 3-phenyl-5-alkoxy-1,3,4-oxdiazole-2-one for producing medicaments that inhibit pancreatic lipase |
| 09/04/2003 | WO2003072097A1 Pharmaceutical composition comprising a bisphosphonate and a cox-2 inhibitor for the treatment of bone diseases |
| 09/04/2003 | WO2003072096A1 Use of folates for producing a preparation suitable for preventing and treating inflammation and diseases associated with inflammation, especially for influencing the inflammation markers crp and saa |
| 09/04/2003 | WO2003072090A2 Use of tyrosine kinase inhibitors for treating cns disorders |
| 09/04/2003 | WO2003072085A1 Solid preparations with improved absorbability of hardly water-soluble drug |
| 09/04/2003 | WO2003072077A1 A substantially visibly transparent topical physical sunscreen formulation |
| 09/04/2003 | WO2003072061A2 Methods and compositions for treating gastrointestinal toxicity induced by cytoablative therapy |
| 09/04/2003 | WO2003072055A2 Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective mao inhibitors |
| 09/04/2003 | WO2003072046A2 Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances |
| 09/04/2003 | WO2003072035A2 Compositions and methods for the treatment of immune related diseases |
| 09/04/2003 | WO2003072029A2 Methods of extending corneal graft survival |
| 09/04/2003 | WO2003072027A2 Compositions and formulations of 9- nitrocamptothecin polymorphs and methods of use thereof |
| 09/04/2003 | WO2003072017A2 Macromolecular conjugates and processes for preparing same |
| 09/04/2003 | WO2003071922A2 Use of modulators of nicotinic receptors for treatment of cognitive dysfunction |
| 09/04/2003 | WO2003064451A3 MODULATION OF TYPE IIβ PHOSPHOINOSITIDE PHOSPHATE KINASE |
| 09/04/2003 | WO2003063840A3 Transmucosal delivery of proton pump inhibitors |
| 09/04/2003 | WO2003062209A3 Substituted quinazolin-4-ylamine analogues as modulators of capsaicin |
| 09/04/2003 | WO2003057006A3 Use of antibodies against the muc18 antigen |
| 09/04/2003 | WO2003053224A3 Novel compositions and methods for cancer |
| 09/04/2003 | WO2003051302A3 Methods and compositions for treatment of central nervous system disorders |
| 09/04/2003 | WO2003048120A3 2-aryl pyrrologpyrimidines for a1 and a3 receptors |
| 09/04/2003 | WO2003046560A3 Self-assembly molecules |
| 09/04/2003 | WO2003045313A3 2-aminoquinoline compounds |
| 09/04/2003 | WO2003035646A3 Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-ht2b receptor antagonist |
| 09/04/2003 | WO2003028730A3 Pharmaceutical combinations of pde-v inhibitors and other agents |
| 09/04/2003 | WO2003024967A3 Indolizines as kinase protein inhibitors |
| 09/04/2003 | WO2003020273A3 Pharmaceutical composition comprising gabapentin or an analogue thereof and an $g(a)-aminoamide and its analgesic use |